BioSight
Companies
Century Therapeutics, Inc. logo

IPSC

NASDAQPHILADELPHIA, PA
Century Therapeutics, Inc.

Century Therapeutics develops cell therapies derived from induced pluripotent stem cells (iPSCs) to treat immuno-oncology, autoimmune, and inflammatory diseases, as well as diabetes. The company is in early-stage development, conducting preclinical studies and clinical trials for multiple product candidates. Century is a pre-revenue biotech firm working to advance its pipeline toward regulatory approval and eventual commercialization.

Price history not yet available for IPSC.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar